CG Oncology (CGON) News Today $27.85 -0.37 (-1.31%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$27.89 +0.04 (+0.14%) As of 02/21/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus PT from BrokeragesFebruary 21 at 1:33 AM | americanbankingnews.comTimesSquare Capital Management LLC Acquires 109,835 Shares of CG Oncology, Inc. (NASDAQ:CGON)TimesSquare Capital Management LLC raised its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 25.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 546,904 shares of the company's stock after purchFebruary 20 at 4:46 AM | marketbeat.comCG Oncology (NASDAQ:CGON) & OKYO Pharma (NASDAQ:OKYO) Head to Head AnalysisFebruary 19 at 2:07 AM | americanbankingnews.comCG Oncology, Inc. (NASDAQ:CGON) Sees Large Growth in Short InterestCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 6,780,000 shares, a growth of 6.4% from the January 15th total of 6,370,000 shares. Based on an average daily volume of 697,900 shares, the short-interest ratio is presently 9.7 days. Currently, 15.2% of the company's stock are short sold.February 19 at 12:47 AM | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Buy" by AnalystsCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been given a consensus rating of "Buy" by the ten analysts that are covering the company, MarketBeat reports. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month tFebruary 18, 2025 | marketbeat.comCG Oncology, Inc. (CGON) Gets a Buy from Bank of America SecuritiesFebruary 13, 2025 | markets.businessinsider.comCG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62%February 3, 2025 | finance.yahoo.comChina Universal Asset Management Co. Ltd. Makes New Investment in CG Oncology, Inc. (NASDAQ:CGON)China Universal Asset Management Co. Ltd. acquired a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 14,340 shares of the company's stock, valued at approxiFebruary 3, 2025 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Stock Holdings Boosted by JPMorgan Chase & Co.JPMorgan Chase & Co. boosted its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 59.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 31,071 shares of the company's stock after purchasing an additJanuary 25, 2025 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Buy" from AnalystsCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been assigned a consensus rating of "Buy" from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendatJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Forecasts CG Oncology FY2025 EarningsCG Oncology, Inc. (NASDAQ:CGON - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for CG Oncology in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will postJanuary 23, 2025 | marketbeat.comInsider Selling: CG Oncology, Inc. (NASDAQ:CGON) Director Sells 1,000 Shares of StockJanuary 15, 2025 | insidertrades.comCG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 SharesCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.January 14, 2025 | marketbeat.comA First Take On CG OncologyJanuary 11, 2025 | seekingalpha.comPfizer study impact on CG Oncology to be minimal, says H.C. WainwrightJanuary 10, 2025 | markets.businessinsider.comCG Oncology Amends Key Executive Employment AgreementsJanuary 10, 2025 | tipranks.comCG Oncology (NASDAQ:CGON) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of CG Oncology in a report on Friday.January 10, 2025 | marketbeat.comCG Oncology initiated with a Buy at TD CowenJanuary 8, 2025 | markets.businessinsider.comCG Oncology, Inc. (CGON) Receives a Buy from TD CowenJanuary 8, 2025 | markets.businessinsider.comTD Cowen Initiates Coverage of CG Oncology (CGON) with Buy RecommendationJanuary 8, 2025 | msn.comCG Oncology (NASDAQ:CGON) Stock Price Up 7.5% - Time to Buy?CG Oncology (NASDAQ:CGON) Trading 7.5% Higher - Still a Buy?January 7, 2025 | marketbeat.comCG Oncology (NASDAQ:CGON) Now Covered by TD CowenTD Cowen started coverage on shares of CG Oncology in a research note on Tuesday. They set a "buy" rating for the company.January 7, 2025 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Sees Large Drop in Short InterestCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 4,990,000 shares, a decline of 5.3% from the November 30th total of 5,270,000 shares. Based on an average daily trading volume, of 590,900 shares, the days-to-cover ratio is currently 8.4 days. Currently, 11.9% of the company's shares are short sold.January 1, 2025 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Price Down 6.9% - Time to Sell?CG Oncology (NASDAQ:CGON) Shares Down 6.9% - Here's WhyDecember 30, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of "Buy" by BrokeragesShares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) have been given a consensus recommendation of "Buy" by the nine analysts that are currently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to thDecember 30, 2024 | marketbeat.comCG Oncology (NASDAQ:CGON) Stock Price Up 2.5% - Here's WhyCG Oncology (NASDAQ:CGON) Trading 2.5% Higher - Still a Buy?December 27, 2024 | marketbeat.comGeode Capital Management LLC Has $40.70 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)Geode Capital Management LLC boosted its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 96.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,078,527 shares of the company's stock after purchasing an additDecember 25, 2024 | marketbeat.comBarclays PLC Increases Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)Barclays PLC raised its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 331.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 90,520 shares of the company's stock after buying an additional 69,523 shares during the quarter. BarDecember 24, 2024 | marketbeat.comCG Oncology Enters Oversold Territory (CGON)December 22, 2024 | nasdaq.comCG Oncology (NASDAQ:CGON) Shares Down 4.3% - Should You Sell?CG Oncology (NASDAQ:CGON) Shares Down 4.3% - Here's What HappenedDecember 19, 2024 | marketbeat.comState Street Corp Raises Stake in CG Oncology, Inc. (NASDAQ:CGON)State Street Corp raised its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 73.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,700,653 shares of the company's stock after purchasing an adDecember 19, 2024 | marketbeat.comCG Oncology, Inc. (NASDAQ:CGON) Director Sells $19,600,000.00 in StockDecember 18, 2024 | insidertrades.comCG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Franklin Resources Inc.Franklin Resources Inc. grew its stake in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 8.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,230,193 shares of the company'sDecember 18, 2024 | marketbeat.comHong Fang Song Sells 700,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) StockCG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Hong Fang Song sold 700,000 shares of the business's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $28.00, for a total value of $19,600,000.00. Following the sale, the director now owns 3,003,931 shares in the company, valued at approximately $84,110,068. The trade was a 18.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.December 17, 2024 | marketbeat.comCG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesDecember 17, 2024 | markets.businessinsider.comCG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesDecember 16, 2024 | globenewswire.comJane Street Group LLC Grows Position in CG Oncology, Inc. (NASDAQ:CGON)Jane Street Group LLC raised its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 240.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 195,951 shares of the company's stock after buying an additional 138,400 shares durDecember 15, 2024 | marketbeat.comCG Oncology 8M share Secondary priced at $28.00December 14, 2024 | markets.businessinsider.comWellington Management Group LLP Has $19.25 Million Stake in CG Oncology, Inc. (NASDAQ:CGON)Wellington Management Group LLP raised its position in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 153.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 510,219 shares of the company's stock after purchasing an additional 308,852 shares during the peDecember 14, 2024 | marketbeat.comCG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of CretostimogeneDecember 13, 2024 | seekingalpha.comCG Oncology (NASDAQ:CGON) Sees Unusually-High Trading Volume - Should You Buy?CG Oncology (NASDAQ:CGON) Sees Strong Trading Volume - Here's What HappenedDecember 13, 2024 | marketbeat.comFmr LLC Raises Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)Fmr LLC boosted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 83,581.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 145,606 shares of the company's stock after purchasing an additionalDecember 13, 2024 | marketbeat.comCG Oncology Announces Pricing of Public OfferingDecember 12, 2024 | globenewswire.comNeo Ivy Capital Management Invests $1.12 Million in CG Oncology, Inc. (NASDAQ:CGON)Neo Ivy Capital Management bought a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 29,678 shares of the company's stock, valued at approximately $1,120,000. Other iDecember 12, 2024 | marketbeat.comCG Oncology Announces Proposed Public OfferingDecember 11, 2024 | globenewswire.comCG Oncology, Inc. (NASDAQ:CGON) Stake Boosted by BNP Paribas Financial MarketsBNP Paribas Financial Markets increased its stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 876.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,660 shares of the company's stock after puDecember 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $14.33 Million Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON)Charles Schwab Investment Management Inc. boosted its holdings in CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 114.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 379,664 shares of the companyDecember 9, 2024 | marketbeat.comLeonard E. Post Sells 1,000 Shares of CG Oncology, Inc. (NASDAQ:CGON) StockDecember 7, 2024 | insidertrades.comPromising Clinical Results and Strategic Positioning: CG Oncology Recommended as a BuyDecember 6, 2024 | markets.businessinsider.comDemystifying CG Oncology: Insights From 7 Analyst ReviewsDecember 6, 2024 | benzinga.com Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Media Mentions By Week CGON Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGON News Sentiment▼1.030.60▲Average Medical News Sentiment CGON News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGON Articles This Week▼53▲CGON Articles Average Week Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Ascendis Pharma A/S News Today Revolution Medicines News Today Blueprint Medicines News Today Legend Biotech News Today Axsome Therapeutics News Today Telix Pharmaceuticals Limited American Depositary Shares News Today Lantheus News Today BridgeBio Pharma News Today Nuvalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGON) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
